IVERMED Trademark

Trademark Overview


On Friday, March 18, 2022, a trademark application was filed for IVERMED with the United States Patent and Trademark Office. The USPTO has given the IVERMED trademark a serial number of 97319437. The federal status of this trademark filing is REGISTERED as of Tuesday, May 21, 2024. This trademark is owned by Right2Try Inc.. The IVERMED trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical compositions and medicaments for use in treatment of cancer; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, inhibiting the proliferation, metastasis and angiogenic activity of malignant cells; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, regulation of one or more kinase signaling pathway, reversing multi-drug resistance, inhibiting tumor stem cells; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, providing anti-inflammatory and antiviral properties; Pharmaceutical compositions and medicaments for use in the treatment of cancer
ivermed

General Information


Serial Number97319437
Word MarkIVERMED
Filing DateFriday, March 18, 2022
Status700 - REGISTERED
Status DateTuesday, May 21, 2024
Registration Number7392450
Registration DateTuesday, May 21, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 25, 2023

Trademark Statements


Goods and ServicesPharmaceutical compositions and medicaments for use in treatment of cancer; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, inhibiting the proliferation, metastasis and angiogenic activity of malignant cells; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, regulation of one or more kinase signaling pathway, reversing multi-drug resistance, inhibiting tumor stem cells; Pharmaceutical compositions and medicaments for use in treatment of a disease or condition in a subject, namely, providing anti-inflammatory and antiviral properties; Pharmaceutical compositions and medicaments for use in the treatment of cancer

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, April 14, 2023
Primary Code005
First Use Anywhere DateFriday, March 18, 2022
First Use In Commerce DateFriday, December 1, 2023

Trademark Owner History


Party NameRight2Try Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressLewes, DE 19958

Party NameRight2Try Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLewes, DE 19958

Party NameRight2Try Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLewes, DE 19958

Trademark Events


Event DateEvent Description
Wednesday, February 15, 2023TEAS VOLUNTARY AMENDMENT RECEIVED
Thursday, March 24, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 29, 2022ASSIGNED TO EXAMINER
Friday, December 30, 2022NON-FINAL ACTION WRITTEN
Friday, December 30, 2022NON-FINAL ACTION E-MAILED
Friday, December 30, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, February 15, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 15, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, February 15, 2023PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Thursday, February 16, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, April 14, 2023NON-FINAL ACTION WRITTEN
Friday, April 14, 2023NON-FINAL ACTION E-MAILED
Friday, April 14, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 8, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, June 8, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 9, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, June 17, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, July 25, 2023PUBLISHED FOR OPPOSITION
Wednesday, July 5, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 25, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 19, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, February 12, 2024TEAS STATEMENT OF USE RECEIVED
Monday, February 12, 2024USE AMENDMENT FILED
Monday, March 4, 2024STATEMENT OF USE PROCESSING COMPLETE
Monday, March 4, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, April 11, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, April 12, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, May 21, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, May 21, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED